Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
23.36 USD | -2.30% | -2.46% | +9.06% |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
- The company has a poor ESG score according to Refinitiv, which ranks companies by sector.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company has insufficient levels of profitability.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+9.06% | 653M | D+ | ||
+9.83% | 118B | B+ | ||
+10.80% | 106B | B+ | ||
-10.84% | 23.4B | B+ | ||
-1.69% | 22.1B | B | ||
-10.23% | 18.34B | A- | ||
-41.92% | 16.59B | A- | ||
-15.11% | 15.97B | B | ||
+6.62% | 14.03B | C+ | ||
+17.53% | 11.67B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ANAB Stock
- Ratings AnaptysBio, Inc.